August 21, 2014 6:21 PM ET

Diversified Consumer Services

Company Overview of University of California-Los Angeles

Company Overview

University of California-Los Angeles is an educational institution offering undergraduate and graduate programs such as arts and architecture, dentistry, education and information studies, law, management, medicine, nursing, and public health. The schools of the university include The College of Letters and Science, offering programs such as social sciences, humanities, life sciences, physical sciences, and honors; The Henry Samueli School of Engineering and Applied Science; School of the Arts and Architecture; School of Theater, Film and Television; School of Nursing; and School of Public Policy and Social Research. University of California - Los Angeles was founded in 1919 and is based in ...

405 Hilgard Avenue

Los Angeles, CA 90095-1361

United States

Founded in 1919

Phone:

310-825-4321

Key Executives for University of California-Los Angeles

Chancellor
Age: 65
Professor in the Department of Molecular and Medical Pharmacology
Age: 72
Visiting Professor
Age: 66
Executive Vice Chancellor and Provost
Executive Director of the Wireless Health Institute
Age: 61
Compensation as of Fiscal Year 2014.

University of California-Los Angeles Key Developments

FIbrocell Science Signs Exclusive Technology Licensing Pact with University of California-Los Angeles

Fibrocell Science announced that it has entered into an exclusive license agreement with The Regents of the University of California. Under the agreement, Fibrocell acquired the rights to commercially apply patented discoveries and technologies resulting from the ongoing scientific collaboration between the University of California at Los Angeles (UCLA) and Fibrocell Science. The technologies from the UCLA collaboration and exclusive license agreements enable Fibrocell to expand its proprietary Personalized Biologics platform which uses human fibroblasts and stem cells from skin to create localized therapies that are compatible with the biology of each patient. The license agreements build upon an existing research collaboration between Fibrocell and UCLA that has already yielded discoveries and technologies related to stem cells and regenerative cells in human skin.

Fibrocell Science, Inc. Announces Technology License Agreements with University of California-Los Angeles to Advance the Development of Personalized Cell Therapies

Fibrocell Science Inc. announced that it has entered into an exclusive license agreement with The Regents of the University of California. Under the agreement, Fibrocell acquired the rights to commercially apply patented discoveries and technologies resulting from the ongoing scientific collaboration between the University of California at Los Angeles (UCLA) and Fibrocell Science. The technologies from the UCLA collaboration and exclusive license agreements enable Fibrocell to expand its proprietary Personalized Biologics platform which uses human fibroblasts and stem cells from skin to create localized therapies that are compatible with the unique biology of each patient. Specifically, the newly licensed patents and technologies relate to two advancements in the therapeutic application of cell therapies: Methods for use of autologous fibroblasts for developing personalized biologics with bone morphogenetic protein 2 (BMP-2) for bone repair, opening the potential for optimal therapeutic effect of BMP-2 at the site of disease in surgical procedures involving bone repair; Methods for producing highly stable, commercially viable induced pluripotent stem cells (iPSCs) from adult skin cells, opening the potential to expand the usage of iPSCs in autologous cell therapies. The license agreements build upon an existing research collaboration between Fibrocell and UCLA that has already yielded discoveries and technologies related to stem cells and regenerative cells in human skin.

ImaginAb Enters into Exclusive Licensing Agreement with UCLA for Immune Cell Imaging Agents

ImaginAb Inc. and the Regents of the University of California, Los Angeles (UCLA) have executed a technology licensing agreement relating to novel immune cell-targeting agents for imaging with Positron Emission Tomography (PET). Inflammation and immune response play a fundamental role in a wide variety of diseases including cancer and autoimmune diseases. Under the agreement, ImaginAb gains exclusive access to novel imaging agents that target specific markers of murine T-cells, enabling a new understanding of response to immunotherapeutic drugs in pre-clinical models. These research "ImmunoPET" imaging agents complement ImaginAb's active clinical development programs, particularly in the cancer immunotherapy space. The imaging of T-cell targets such as CD3 and CD8 has the potential to improve on the limited efficacy of tissue and blood-based biomarker strategies to effectively predict and monitor response to drugs against important targets like PD-1/L1 or CTLA4 checkpoint inhibitors.

Similar Private Companies By Industry

Company Name Region
Radiant Services Corp. United States
Autism Training Solutions L.L.C. United States
E&M Mayock and Associates PC United States
La Bella Party Rental Company United States
Frederic Fekkai Melrose Place, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact University of California-Los Angeles, please visit www.ucla.edu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.